What are the effects of sirolimus?

Sirolimus (sirolimus) is indicated for the prevention of organ rejection (TR) in patients over 13 years of age who have received kidney transplants. For patients with low to moderate immune risk, it is recommended that rapamycin be used first in a combination regimen of cyclosporine and corticosteroids, with cyclosporine discontinued 2-months after transplant; patients with high immune risk (defined as black recipients and/or repeat kidney transplant recipients who have lost a previous allograft for immune reasons) and/or in patients with high group-reactive antibodies [peak PRA levels >80%]), sirolimus is recommended in combination with cyclosporine and corticosteroids during the first year after transplantation and is also indicated for the treatment of patients with pulmonary lymphangioleiomyomatosis (LAM).